Wall Street Zen Downgrades DiaMedica Therapeutics (NASDAQ:DMAC) to Sell
Wall Street Zen has downgraded DiaMedica Therapeutics (NASDAQ:DMAC) from a "hold" to a "sell" rating. Despite this, other analysts have given the stock a "buy" rating with price targets ranging from $11.00 to $14.00. The stock opened at $5.71, down 2.7%, with a market cap of $295.15 million. Major shareholder Jan Stahlberg recently increased his stake by purchasing over 1.5 million shares. Institutional investors hold 10.12% of the company, which focuses on treatments for acute ischemic stroke and cardio-renal disease.
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Tuesday.
Other equities research analysts have also recently issued research reports about the stock. Craig Hallum lifted their price target on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Friday, July 18th. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Finally, Lake Street Capital lifted their price target on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Friday, July 18th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $12.33.
Get DiaMedica Therapeutics alerts:
Get Our Latest Stock Report on DMAC
DiaMedica Therapeutics Stock Down 2.7%
Shares of NASDAQ DMAC opened at $5.71 on Tuesday. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $6.82. The stock's 50 day moving average price is $4.70 and its 200-day moving average price is $4.55. The company has a market capitalization of $295.15 million, a PE ratio of -8.28 and a beta of 1.40.
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.18). As a group, research analysts expect that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.
Insider Buying and Selling at DiaMedica Therapeutics
In other news, major shareholder Jan Stahlberg purchased 1,542,857 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were purchased at an average price of $3.50 per share, with a total value of $5,399,999.50. Following the completion of the acquisition, the insider owned 6,764,465 shares in the company, valued at $23,675,627.50. This trade represents a 29.55% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.30% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in DMAC. Raymond James Financial Inc. bought a new position in shares of DiaMedica Therapeutics in the fourth quarter worth $83,000. Barclays PLC purchased a new position in DiaMedica Therapeutics in the fourth quarter worth $151,000. Dimensional Fund Advisors LP grew its position in DiaMedica Therapeutics by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company's stock worth $105,000 after acquiring an additional 2,380 shares in the last quarter. Susquehanna International Group LLP grew its position in DiaMedica Therapeutics by 269.5% in the fourth quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after acquiring an additional 273,395 shares in the last quarter. Finally, Northern Trust Corp grew its position in DiaMedica Therapeutics by 49.8% in the fourth quarter. Northern Trust Corp now owns 180,192 shares of the company's stock worth $978,000 after acquiring an additional 59,902 shares in the last quarter. Institutional investors own 10.12% of the company's stock.
DiaMedica Therapeutics Company Profile
(Get Free Report)DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Read More
- Five stocks we like better than DiaMedica Therapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Healthcare Pathbreakers With Long-Term Tailwinds
- Trading Halts Explained
- 3 Tariff-Proof Retailers Making New All-time Highs
- Are Penny Stocks a Good Fit for Your Portfolio?
- With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in DiaMedica Therapeutics Right Now?
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
